Patents Examined by Deepak R. Rao
  • Patent number: 11680068
    Abstract: The present invention relates to compounds of formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, bonds a, b, c and d, X1, X2, X3, X4, R2, and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.
    Type: Grant
    Filed: May 6, 2022
    Date of Patent: June 20, 2023
    Assignee: Cancer Research Technology Limited
    Inventors: Allan Jordan, Rebecca Newton, George Hynd, Jonathan Mark Sutton, Bohdan Waszkowycz
  • Patent number: 11672791
    Abstract: Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein X, Y and Z are as described herein. In certain embodiments, a compound disclosed herein inhibits a cellular TAM receptor, and can be used to treat disease mediated by or involving the TAM receptor family.
    Type: Grant
    Filed: September 2, 2021
    Date of Patent: June 13, 2023
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Sacha Holland, Rajinder Singh, Somasekhar Bhamidipati, Pingyu Ding, Rao Kolluri, Ihab Darwish, Esteban Masuda, Jiaxin Yu
  • Patent number: 11667611
    Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: June 6, 2023
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Ankush Argade, Arvinder Sran, David Carroll, Jeffrey Clough, Kin Tso, Somasekhar Bhamidipati, Sambaiah Thota, Rajinder Singh, Vanessa Taylor, Hui Li, Esteban Masuda
  • Patent number: 11666570
    Abstract: Methods are provided for treatment of skin cancers and squamous cell carcinomas by inhibition of RET activity. The treatment can reduce cancer development and progression; and can reduce metastasis and invasion, including perineural invasion.
    Type: Grant
    Filed: July 2, 2020
    Date of Patent: June 6, 2023
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventor: Carolyn Lee
  • Patent number: 11661406
    Abstract: A method of preparing an intermediate useful for the synthesis of a diphenylmethane derivative that can be used as an SGLT inhibitor is described. A method of synthesizing a compound of Formula 7 can address problems of existing synthesis processes requiring the synthesis of the Grignard reagent and management of related substances. In addition, the method can minimize the generation of related substances, and thus does not require reprocessing of reaction products, thereby simplifying the process. Accordingly, the production yield of a diphenylmethane derivative can be maximized.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: May 30, 2023
    Inventors: Qing Ri Li, Hee Kyoon Yoon
  • Patent number: 11661426
    Abstract: Disclosed are compounds of formula I, II, III, and IV, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of ALK2 kinase. Also provided are pharmaceutical compositions comprising a compound of formula I, II, III, or IV, or pharmaceutically acceptable salt thereof, and methods involving use of the compounds or pharmaceutically acceptable salts thereof and compositions in the treatment and prevention of various diseases and conditions, such as fibrodysplasia ossificans progressiva.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: May 30, 2023
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, V. Satish Kumar, Weihe Zhang, Peng-Cheng Lu, Krishnan Raman
  • Patent number: 11661400
    Abstract: The present disclosure relates to a compound of Formula I, or a geometric isomer, enantiomer, diastereomer, racemate, atropisomer, pharmaceutically acceptable salt, prodrug or solvate thereof. The present disclosure further relates to a composition comprising the compound of Formula (I). The compound and the composition described herein can be used to inhibit NADPH oxidase activity.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: May 30, 2023
    Inventors: Syaulan S. Yang, Kuang Yuan Lee, Meng Hsien Liu, Yan-Feng Jiang, Yu-Shiou Fan, Chiung Wen Wang, Mei-Chi Hsu
  • Patent number: 11656384
    Abstract: An object of the present invention is to provide a composition capable of forming a film having a high refractive index and excellent exterior characteristics. Another object of the present invention is to provide a film, a lens, and a solid-state imaging element in which the composition is used. Still another object of the present invention is to provide novel compounds. The composition according to an embodiment of the present invention contains a compound represented by General Formula (I), a solvent, and a resin, in which a solubility of the compound represented by General Formula (I) in the solvent is less than 0.5% by mass at 25° C., and a maximum absorption wavelength of the compound represented by General Formula (I) at a wavelength range of 300 to 800 nm is equal to or shorter than 450 nm.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: May 23, 2023
    Assignee: FUJIFILM Corporation
    Inventors: Yushi Kaneko, Yoshinori Taguchi, Hirotaka Takishita, Masahiro Mori, Yasuhiro Sawamura
  • Patent number: 11649212
    Abstract: The present invention provides compounds of formula (I), formula (II) or formula (III), wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: May 16, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: James Aaron Balog, Emily Charlotte Cherney, Weifang Shan, David K. Williams, Liping Zhang
  • Patent number: 11643397
    Abstract: The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
    Type: Grant
    Filed: July 23, 2021
    Date of Patent: May 9, 2023
    Assignee: GlaxoSmithKline LLC
    Inventors: Kevin J. Duffy, Duke M. Fitch, Jian Jin, Ronggang Liu, Antony N. Shaw, Kenneth Wiggall
  • Patent number: 11643405
    Abstract: The invention discloses compounds for treatment or prevention of liver diseases. The compounds are compounds represented by a formula (I) or (II), optical isomers or pharmaceutically acceptable salts of the compounds. The compounds and optical isomers or pharmaceutically acceptable salts of the compounds can be applied to preparation of drugs for treatment or prevention of liver diseases.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: May 9, 2023
    Inventors: Dongfang Shi, Changjin Fu, Xi Cheng, Weiwei Gong, Jie Gu, Pengfei Li, Min Zhang, Yan Yang, Wenqing Jin
  • Patent number: 11634410
    Abstract: Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
    Type: Grant
    Filed: March 23, 2021
    Date of Patent: April 25, 2023
    Assignee: Pfizer Inc.
    Inventors: Matthew Dowling, Dilinie Fernando, Kentaro Futatsugi, Kim Huard, Thomas Victor Magee, Brian Raymer, Andre Shavnya, Aaron Smith, Benjamin Thuma, Andy Tsai, Meihua Tu
  • Patent number: 11634409
    Abstract: Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.
    Type: Grant
    Filed: May 16, 2022
    Date of Patent: April 25, 2023
    Assignee: Array BioPharma Inc.
    Inventors: Patrick Michael Barbour, Katie Keaton Brown, Adam Wade Cook, Erik James Hicken, Dean Russell Kahn, Ellen Ruth Laird, Andrew Terrance Metcalf, David Austin Moreno, Bradley Jon Newhouse, Spencer Phillip Pajk, Brett Joseph Prigaro, Li Ren, Eugene Tarlton
  • Patent number: 11629149
    Abstract: The invention provides compounds of Formula (I): as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: April 18, 2023
    Assignee: Novartis AG
    Inventors: Maxime Dauphinais, Rama Jain, Dennis Christofer Koester, James R. Manning, Vanessa Marx, Daniel Poon, Lifeng Wan, Xiaojing Michael Wang, Aregahegn Yifru, Qian Zhao
  • Patent number: 11629151
    Abstract: Provided is a synthetic intermediate for the preparation of photochromic indolenaphthopyran compounds having the core skeletal structure of Formula (I): wherein m is 0 to 4, n is 0 to 4, R1 and R2 are each independently hydroxyl, cyano, (meth)acrylate, amino, halo, substituted or unsubstituted alkyl, boronic ester, boronic acid, polyether, polyester, polycarbonate, polyurethane, substituted or unsubstituted aryl, substituted or unsubstituted heterocycloaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted arylthio, ketone, aldehyde, ester, carboxylic acid, carboxylate, amide, carbonate, carbamate, urea, siloxane, alkoxysilane, or polysiloxane; R3 is substituted or unsubstituted 2-pyridyl or substituted or unsubstituted 2-quinolyl; and R4 is hydrogen, substituted or unsubstituted alkyl, alkoxymethyl, substituted or unsubstituted silyl, or acyl.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: April 18, 2023
    Assignee: Transitions Optical, Ltd.
    Inventors: Ryan Stayshich, Robert W. Walters
  • Patent number: 11618746
    Abstract: The disclosure provides a compound of Formula (I), including deuterated derivatives, pharmaceutically acceptable salts, and solvates thereof, solid state forms of those compounds, compositions comprising those compounds and solid forms, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: April 4, 2023
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jingrong Cao, Jon H. Come, Leslie A. Dakin, Francois Denis, Warren A. Dorsch, Anne Fortier, Martine Hamel, Elaine B. Krueger, Brian Ledford, Suganthini S. Nanthakumar, Olivier Nicolas, Camil Sayegh, Timothy J. Senter, Tiansheng Wang, Michael Brodney, Kan-Nian Hu, Peter Rose, Kevin Gagnon, Yi Shi, Muna Shrestha, Ales Medek, Faith Witkos
  • Patent number: 11612599
    Abstract: Compounds of formula (I), wherein A, R, W, Q, n and m have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: March 28, 2023
    Assignee: Asceneuron SA
    Inventors: Anna Quattropani, Santosh S. Kulkarni, Awadut Gajendra Giri
  • Patent number: 11584760
    Abstract: Disclosed herein, inter alia, are compositions and methods of using the same for the treatment of cancer.
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: February 21, 2023
    Inventors: Sangkil Nam, David Horne, Larry Eugene Overman, Brad Loertscher
  • Patent number: 11583529
    Abstract: The present disclosure provides compounds and methods of use thereof for treating inflammatory diseases or disorders.
    Type: Grant
    Filed: May 24, 2021
    Date of Patent: February 21, 2023
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Susan Macdonald, Adna Halilovic
  • Patent number: 11584746
    Abstract: The application relates to a compound having Formula Ia or Ib: or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: February 21, 2023
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael S. Gray, Dries De Clercq, Jaebong Jang, Pasi Janne, Ciric To, Michael Eck, Eunyoung Park, David Heppner